These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 23791369)

  • 21. Shifting exudative age-related macular degeneration patients to ranibizumab after insufficient response to bevacizumab.
    de Geus SJ; Jager MJ; Luyten GP; Dijkman G
    Acta Ophthalmol; 2013 Aug; 91(5):e411-3. PubMed ID: 23551594
    [No Abstract]   [Full Text] [Related]  

  • 22. Outcomes of cataract surgery in patients with neovascular age-related macular degeneration in the era of anti-vascular endothelial growth factor therapy.
    Tabandeh H; Chaudhry NA; Boyer DS; Kon-Jara VA; Flynn HW
    J Cataract Refract Surg; 2012 Apr; 38(4):677-82. PubMed ID: 22284725
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Growth of type 1 neovascularization following cessation of anti-vascular endothelial growth factor therapy as a possible explanation for treatment resistance.
    Shah VP; Freund KB
    JAMA Ophthalmol; 2013 Jul; 131(7):967-9. PubMed ID: 23846209
    [No Abstract]   [Full Text] [Related]  

  • 24. One-year outcomes of aflibercept in recurrent or persistent neovascular age-related macular degeneration.
    Iacono P; Battaglia Parodi M; Bandello F
    Am J Ophthalmol; 2015 May; 159(5):996-7. PubMed ID: 25867595
    [No Abstract]   [Full Text] [Related]  

  • 25. Short-Term Changes in Choroidal Thickness After Aflibercept Therapy for Neovascular Age-Related Macular Degeneration.
    Kim JH
    Am J Ophthalmol; 2015 Jul; 160(1):207. PubMed ID: 26054473
    [No Abstract]   [Full Text] [Related]  

  • 26. Retreatment with anti-vascular endothelial growth factor therapy based on changes in visual acuity after initial stabilization of neovascular age-related macular degeneration: 3-year follow-up results.
    Dunavoelgyi R; Sacu S; Eibenberger K; Palkovits S; Leydolt C; Pruente C; Schmidt-Erfurth U
    Retina; 2012 Sep; 32(8):1471-9. PubMed ID: 22414958
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reply.
    Eadie JA; Ip MS
    Retina; 2016 Feb; 36(2):e10-2. PubMed ID: 26696314
    [No Abstract]   [Full Text] [Related]  

  • 28. Correspondence.
    Călugăru D; Călugăru M
    Retina; 2016 Feb; 36(2):e9-e10. PubMed ID: 26655619
    [No Abstract]   [Full Text] [Related]  

  • 29. Correspondence.
    Bindra CS; Sen A; Mitra A; Bhushan B
    Retina; 2015 Aug; 35(8):e54. PubMed ID: 26166801
    [No Abstract]   [Full Text] [Related]  

  • 30. Correspondence.
    Bronkhorst IH; Marinkovic M; Dijkman G; Boon CJ
    Retina; 2015 Aug; 35(8):e52-4. PubMed ID: 26166799
    [No Abstract]   [Full Text] [Related]  

  • 31. Reply: To PMID 24999721.
    Eadie JA; Ip MS
    Retina; 2015 Aug; 35(8):e54-5. PubMed ID: 26166802
    [No Abstract]   [Full Text] [Related]  

  • 32. Randomized study of bevacizumab vs ranibizumab for age-related macular degeneration: inappropriate conclusions.
    Messori A; Fadda V; Trippoli S
    Am J Ophthalmol; 2010 May; 149(5):867; author reply 867. PubMed ID: 20399931
    [No Abstract]   [Full Text] [Related]  

  • 33. Variants in the VEGFA gene and treatment outcome after anti-VEGF treatment for neovascular age-related macular degeneration.
    Abedi F; Wickremasinghe S; Richardson AJ; Makalic E; Schmidt DF; Sandhu SS; Baird PN; Guymer RH
    Ophthalmology; 2013 Jan; 120(1):115-21. PubMed ID: 23149126
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treating the untreatable patient: current options for the management of treatment-resistant neovascular age-related macular degeneration.
    Broadhead GK; Hong T; Chang AA
    Acta Ophthalmol; 2014 Dec; 92(8):713-23. PubMed ID: 24925048
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Management of submacular hemorrhage secondary to neovascular age-related macular degeneration with anti-vascular endothelial growth factor monotherapy.
    Shienbaum G; Garcia Filho CA; Flynn HW; Nunes RP; Smiddy WE; Rosenfeld PJ
    Am J Ophthalmol; 2013 Jun; 155(6):1009-13. PubMed ID: 23465269
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Review and expert opinion in age related macular degeneration. Focus on the pathophysiology, angiogenesis and pharmacological and clinical data].
    Weber M; Sennlaub F; Souied E; Cohen SY; Béhar-Cohen F; Milano G; Tadayoni R
    J Fr Ophtalmol; 2014 Sep; 37(7):566-79. PubMed ID: 25190312
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Age-related macular degeneration].
    Kernt M; Wolf A; Kampik A
    MMW Fortschr Med; 2013 Feb; 155(2):43-5; quiz 46-7. PubMed ID: 23573745
    [No Abstract]   [Full Text] [Related]  

  • 38. Clinical predictors of sustained intraocular pressure elevation due to intravitreal anti-vascular endothelial growth factor therapy.
    Hoang QV; Tsuang AJ; Gelman R; Mendonca LS; Della Torre KE; Jung JJ; Freund KB
    Retina; 2013 Jan; 33(1):179-87. PubMed ID: 22990314
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intravitreal ranibizumab injection for neovascular age-related macular degeneration in phakic versus pseudophakic eyes.
    Baek JS; Cho HJ; Cho SW; Kim CG; Kim JW
    Retina; 2013 Mar; 33(3):467-73. PubMed ID: 23400082
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Age-related macular degeneration, anti-VEGF therapy, and ophthalmic imaging: is there a best practice?
    Han DP
    JAMA Ophthalmol; 2013 Sep; 131(9):1124-6. PubMed ID: 23744293
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.